ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 896

Herpes Zoster and the Short Term Risk for Ischemic Stroke in Patients with Autoimmune Diseases

Leonard H. Calabrese1, Fenglong Xie2, Huifeng Yun3, Kevin L. Winthrop4, John Baddley5, Cassandra Calabrese6 and Jeffrey R. Curtis7, 1Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4Oregon Health and Science University, Portland, OR, 5Infectious Diseases, University of Alabama, Birmingham, AL, 6Cleveland Clinic Foundation, Cleveland, OH, 7University of Alabama at Birmingham, Birmingham, AL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: infection and opportunistic infections

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: ACR Plenary Session I: Discovery 2015

Session Type: ACR Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Herpes zoster (HZ) is an opportunistic infection caused by Varicella Zoster Virus (VZV); HZ is observed with increasing frequency in patients on immunosuppressive therapies. HZ is not only a morbid condition but is associated with a variety of complications. Prior literature has suggested that the risk of stroke may increase shortly after an incidence of HZ, but little is known about this association for patients with autoimmune (AI) disease who are at increased risk both for zoster and stroke compared to the general population.

Methods:

Medicare data (2006-2012) was used to identify patients with incident herpes zoster (HZ), defined by at least one ICD9 diagnosis code 053.xx from hospital discharge or outpatient HZ with a prescription for zoster drug within 7 days. Within the preceding 12 months (‘baseline’), they also must have had consecutive coverage with Medicare parts A, B, and D and could not have had any diagnosis code or treatment for HZ.  They must also have had ankylosing spondylitis (AS), inflammable bowel disease (IBD), psoriasis (PSO), psoriatic arthritis (PSA), or rheumatoid arthritis (RA) based on 2+ diagnoses from physician visits. Patients with prior stroke or the occurrence of HZ and stroke on the same day were excluded.

Follow-up started at the date of HZ diagnosis + 1 day. The outcome of interest was hospitalized ischemic stroke. The hypothesis tested was that the incidence of stroke immediately following HZ was increased compared to the incidence of stroke at later time points. Incidence rate of hospitalized ischemic stroke in risk windows of 6 and 12 months following the HZ event were evaluated. Poisson regression was to compute incidence rate ratios (IRRs) and to control for multiple potential confounders potentially associated with stroke, comparing the 1, 6 and 12 month periods after HZ to subsequent time periods.

Results:

A total of 50,929 patients with autoimmune diseases and incident HZ were eligible for analysis. The crude incidence rate of hospitalized ischemic stroke was 9.8/1000py in the 6 months after HZ, compared to 8.7/1000py in years 2-6. After multivariable adjustment for multiple stroke-related factors, the IRR for the risk in the first year compared to the second was 1.30 (1.05 – 1.61) compared to month 12-18. Examining the shorter risk window of 30 days after HZ, the IRR was 1.50 (1.06 – 2.12) compared to the pooled rate in years 2-6. Age, diabetes, hypertension, atrial fibrillation, prior TIA, and higher glucocorticoid doses were also significantly associated with higher stroke risk.

Conclusion:

In patients with autoimmune diseases, incident herpes zoster was associated with a 50% increase risk for stroke in the subsequent month. These data provide urgency for developing strategies to reduce the risk of VZV  in vulnerable immunosuppressed patients.


Disclosure: L. H. Calabrese, BMS, 8,Crescendo, 8,Abbvie, 5,Genentech and Biogen IDEC Inc., 8,Pfizer Inc, 5,Sanofi-Aventis Pharmaceutical, 5,Johnson & Johnson, 8; F. Xie, None; H. Yun, None; K. L. Winthrop, BMS, 2,AbbVie, BMS, UCB, Amgen, 5; J. Baddley, None; C. Calabrese, None; J. R. Curtis, Roche/Genentech, UCB, Janssen, Corrona, Amgen, Pfizer, BMS, Crescendo, AbbVie, 2,Roche/Genentech, UCB, Janssen, Corrona, Amgen, Pfizer, BMS, Crescendo, AbbVie, 5.

To cite this abstract in AMA style:

Calabrese LH, Xie F, Yun H, Winthrop KL, Baddley J, Calabrese C, Curtis JR. Herpes Zoster and the Short Term Risk for Ischemic Stroke in Patients with Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/herpes-zoster-and-the-short-term-risk-for-ischemic-stroke-in-patients-with-autoimmune-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/herpes-zoster-and-the-short-term-risk-for-ischemic-stroke-in-patients-with-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology